D. Boral Capital Reiterates Buy Rating for GeoVax Labs (NASDAQ:GOVX)

D. Boral Capital reiterated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research note released on Friday,Benzinga reports. They currently have a $9.00 price objective on the stock.

Separately, Wall Street Zen downgraded shares of GeoVax Labs from a “hold” rating to a “sell” rating in a research report on Monday, July 21st. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $8.50.

GeoVax Labs Trading Up 0.8%

NASDAQ:GOVX opened at $0.65 on Friday. The business’s fifty day moving average price is $0.72 and its 200 day moving average price is $0.89. The firm has a market capitalization of $10.29 million, a price-to-earnings ratio of -0.32 and a beta of 3.57. GeoVax Labs has a 1-year low of $0.43 and a 1-year high of $3.88.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Monday, July 28th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.06. The company had revenue of $0.85 million for the quarter, compared to analysts’ expectations of $0.37 million. GeoVax Labs had a negative return on equity of 408.80% and a negative net margin of 403.88%. Equities analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current year.

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in GeoVax Labs in the first quarter valued at approximately $27,000. Northern Trust Corp acquired a new position in shares of GeoVax Labs during the 4th quarter worth $29,000. Citadel Advisors LLC bought a new position in shares of GeoVax Labs during the 4th quarter valued at $104,000. Finally, Armistice Capital LLC bought a new position in shares of GeoVax Labs during the 1st quarter valued at $703,000. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.